These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8334424)

  • 21. Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. A case report of cardiovascular toxicity with serial echocardiographic evaluation.
    Schechter D; Nagler A; Ackerstein A; Nassar H; Admon D; Naparstek E; Rein AJ
    Cardiology; 1992; 80(3-4):168-71. PubMed ID: 1511464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
    De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
    J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    West WH; Tauer KW; Yannelli JR; Marshall GD; Orr DW; Thurman GB; Oldham RK
    N Engl J Med; 1987 Apr; 316(15):898-905. PubMed ID: 3493433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
    Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
    Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic strategies of mildly malignant non-Hodgkin's lymphoma].
    Wörmann B; Unterhalt M; Hiddemann W
    Internist (Berl); 1993 Feb; 34(2):132-8. PubMed ID: 8454426
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a.
    Nagler A; Ackerstein A; Barak V; Slavin S
    J Hematother; 1994; 3(1):75-82. PubMed ID: 7922012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment.
    Maffezzini M; Simonato A; Fortis C
    Prostate; 1996 May; 28(5):282-6. PubMed ID: 8610053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
    Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
    Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow.
    Talmadge JE; Reed E; Ino K; Kessinger A; Kuszynski C; Heimann D; Varney M; Jackson J; Vose JM; Bierman PJ
    Bone Marrow Transplant; 1997 Jan; 19(2):161-72. PubMed ID: 9116614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.
    Carella Am; Carlier P; Congiu A; Occhini D; Meloni G; Anselmo AP; Mandelli F; Mazza P; Tura S; Mangoni L
    Leukemia; 1991; 5 Suppl 1():68-71. PubMed ID: 1890870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation.
    Streetly M; Kazmi M; Radia D; Hoyle C; Schey SA
    Bone Marrow Transplant; 2004 Jun; 33(11):1131-5. PubMed ID: 15094743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-alpha and histamine treatment during remission of non-Hodgkin's lymphoma.
    Ahlberg R; MacNamara B; Andersson M; Zheng C; Svensson A; Holm G; Hansson M; Porwit-MacDonald A; Björkholm M; Sundblad A
    Hematol J; 2003; 4(5):336-41. PubMed ID: 14502258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
    Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
    Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation.
    Ratanatharathorn V; Uberti J; Karanes C; Lum LG; Abella E; Dan ME; Hussein M; Sensenbrenner LL
    Bone Marrow Transplant; 1994 May; 13(5):625-30. PubMed ID: 8054915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of advanced renal cell carcinoma with subcutaneous administration of interleukin 2 and interferon-alpha].
    Hofmockel G; Theiss M; Bussen D; Wirth MP; Frohmüller HG
    Urologe A; 1994 Sep; 33(5):434-9. PubMed ID: 7974933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.